While Apixaban’s effectiveness as an AF treatment for stroke prevention remains to be proven in the United States, the European Medicines Agency for Medicinal Products for Human Use (CHMP) is in support of the drug’s use in 27 European countries, including Norway and Iceland.
The CHMP’s decision to use Apixaban for lowering the risk of stroke or systemic embolization associated with nonvalvular atrial fibrillation (AF) was made following the results of the ARISTOTLE and AVERROES clinical trials of the drug. One of those trials showed that Apixaban beat the popular drug Warfarin at stroke prevention; the other trial showed that Apixaban beat aspirin in preventing strokes and embolisms. Before Apixaban is officially approved, the European Commission will have the final say in whether the drug is made widely available across Europe. It helps that the EU already cleared Apixaban for use in preventing venous thromboembolism in those patients who have undergone hip- or knee-replacement surgery.
Apixaban has been competing with the another new anticoagulant medication Dabigatran for global approval. Both drugs are viewed as safer alternatives to Warfarin for stroke prevention in AF patients. All three of those medications are considered safer than another, more infamous anticoagulant medication…Multaq. Research has shown that Multaq causes liver failure and a worsening of the heart condition for some patients. Made by Sano-Aventis, Multaq has been recommended for use only should all other medications fail to work. It is for this reason that many doctors won’t even prescribe Multaq at all.
If you or a loved one has suffered from liver failure or a worsening heart condition after being treated with Multaq, contact the attorneys at Greg Jones today for a free consultation. I am experienced at fighting Multaq lawsuits and may be able to help you recover money for your injuries.